R&D
From in silico to in vivo: Why development strategy now dete...
As discovery becomes faster and more accessible, the differentiator shifts downstream.
R&D
Changing Faces: Pharma and biotech, March 2026
A broad mix of senior leadership and scientific and commercial appointments shaped last month’s pharma and biotech hiring activity.
News
Chinese trial backs base-editing drug for thalassaemia
A landmark study in China has shown that a base-editing therapy developed by CorrectSequence achieved stellar results in beta-thalassaemia.
News
Roche places a $1bn bet on C4T degrader-antibody conjugates
Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.
News
Pulmonary fibrosis drug developer Avalyn files IPO
Avalyn Pharma hops on the IPO train, filing to list on the Nasdaq and raise funds for late-stage trials of its inhaled pulmonary fibrosis therapies.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
